Nothing Special   »   [go: up one dir, main page]

FR2870126A1 - Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin - Google Patents

Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin

Info

Publication number
FR2870126A1
FR2870126A1 FR0405366A FR0405366A FR2870126A1 FR 2870126 A1 FR2870126 A1 FR 2870126A1 FR 0405366 A FR0405366 A FR 0405366A FR 0405366 A FR0405366 A FR 0405366A FR 2870126 A1 FR2870126 A1 FR 2870126A1
Authority
FR
France
Prior art keywords
lentiviral vector
vaccine
expression
applications
recombinant lentiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0405366A
Other languages
English (en)
Other versions
FR2870126B1 (fr
Inventor
Philippe Despres
Pierre Charneau
Frederic Tangy
Marie Pascale Frenkiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0405366A priority Critical patent/FR2870126B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/IB2005/001753 priority patent/WO2005111221A1/fr
Priority to JP2007517517A priority patent/JP2008508863A/ja
Priority to MXPA06013388A priority patent/MXPA06013388A/es
Priority to EP05748053.5A priority patent/EP1751291B1/fr
Priority to CN200580015744XA priority patent/CN1981043B/zh
Priority to US11/596,675 priority patent/US20090214589A1/en
Priority to CA2564934A priority patent/CA2564934C/fr
Priority to EP11167507.0A priority patent/EP2371966B1/fr
Priority to BRPI0510016A priority patent/BRPI0510016B8/pt
Publication of FR2870126A1 publication Critical patent/FR2870126A1/fr
Application granted granted Critical
Publication of FR2870126B1 publication Critical patent/FR2870126B1/fr
Priority to US12/929,215 priority patent/US8716013B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Utilisation d'un vecteur lentiviral recombinant comprenant un fragment polynucléotidique codant pour au moins une protéine d'un virus de la famille des Flaviviridae ou un peptide immunogène d'au moins 8 acides aminés de ladite protéine, pour la préparation d'une composition pharmaceutique destinée à la prévention et/ou au traitement d'une infection à Flaviviridae chez une espèce sensible.
FR0405366A 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin Expired - Lifetime FR2870126B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP11167507.0A EP2371966B1 (fr) 2004-05-17 2005-05-16 Vecteur de lentivirus recombinant pour l'expression d'une protéine de Flaviviridés et applications associées en tant que vaccin
MXPA06013388A MXPA06013388A (es) 2004-05-17 2005-05-16 Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
EP05748053.5A EP1751291B1 (fr) 2004-05-17 2005-05-16 Vecteur lentiviral recombine utilise dans l'expression d'une proteine flaviviridae et utilisations associees de ce vecteur sous forme de vaccin
CN200580015744XA CN1981043B (zh) 2004-05-17 2005-05-16 用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用
US11/596,675 US20090214589A1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
PCT/IB2005/001753 WO2005111221A1 (fr) 2004-05-17 2005-05-16 Vecteur lentiviral recombine utilise dans l'expression d'une proteine flaviviridae et utilisations associees de ce vecteur sous forme de vaccin
JP2007517517A JP2008508863A (ja) 2004-05-17 2005-05-16 フラビウイルス科ウイルスタンパク質発現のための組換えレンチウイルスベクター、及びワクチンとしてのそれらの使用
BRPI0510016A BRPI0510016B8 (pt) 2004-05-17 2005-05-16 vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina
CA2564934A CA2564934C (fr) 2004-05-17 2005-05-16 Vecteur lentiviral recombine utilise dans l'expression d'une proteine flaviviridae et utilisations associees de ce vecteur sous forme de vaccin
US12/929,215 US8716013B2 (en) 2004-05-17 2011-01-07 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin

Publications (2)

Publication Number Publication Date
FR2870126A1 true FR2870126A1 (fr) 2005-11-18
FR2870126B1 FR2870126B1 (fr) 2009-07-17

Family

ID=34945000

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0405366A Expired - Lifetime FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin

Country Status (9)

Country Link
US (2) US20090214589A1 (fr)
EP (2) EP1751291B1 (fr)
JP (1) JP2008508863A (fr)
CN (1) CN1981043B (fr)
BR (1) BRPI0510016B8 (fr)
CA (1) CA2564934C (fr)
FR (1) FR2870126B1 (fr)
MX (1) MXPA06013388A (fr)
WO (1) WO2005111221A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784910B2 (en) 1999-10-12 2006-07-27 Centre National De La Recherche Scientifique Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
EP1939214B1 (fr) 2006-12-22 2013-07-10 Institut Pasteur Cellules et méthodes pour générer des virus à ARN, non-segmenté et de brin négatif
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
AU2009240011A1 (en) * 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
EP2666477A1 (fr) 2012-05-23 2013-11-27 Theravectys Vecteurs lentiviraux contenant un promoteur du MHC classe I
WO2012021741A2 (fr) * 2010-08-12 2012-02-16 Clontech Laboratories, Inc. Dosages à flux latéral pour analytes non diagnostiqués
EP3031923A1 (fr) * 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
CA3003890A1 (fr) 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprenant des vecteurs lentiviraux exprimant l'il-12 et leurs methodes d'utilisation
EP3184119A1 (fr) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatographie basée sur des stratégies de purification pour les virus de la rougeole basés sur un échafaudage
US11305003B2 (en) 2017-11-09 2022-04-19 Institut Pasteur Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909A1 (fr) * 1998-04-24 1999-10-29 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
WO2000075665A1 (fr) * 1999-06-09 2000-12-14 Institut Pasteur Detection precoce des flavivirus en utilisant la clycoproteine ns1
EP1092779A1 (fr) * 1999-10-11 2001-04-18 Institut Pasteur Vecteurs lentiviraux pour la préparation des compositions immunothérapeutiques
US20030104611A1 (en) * 1998-01-16 2003-06-05 Johnston Julie C. Feline immunodeficiency virus gene therapy vectors
CA2456873A1 (fr) * 2003-02-26 2004-08-26 Centre National De La Recherche Scientifique (C.N.R.S.) Proteines du virus du nil occidental, genes codant celles-ci et applications vaccinales, therapeutiques et diagnostiques a base de celles-ci

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586065B1 (fr) * 1992-07-16 2010-03-24 Advanced Life Science Institute, Inc Peptides antigéniques pour grouper le virus de l'hépatite C, nécessaire et méthodes
US5883081A (en) * 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
WO1998017815A1 (fr) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Vecteurs retroviraux
JP4578678B2 (ja) 1997-12-22 2010-11-10 オックスフォード バイオメディカ(ユーケー)リミテッド ウマ伝染性貧血ウイルス(eiav)系
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
AU4554899A (en) 1998-06-09 1999-12-30 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
AU784910B2 (en) 1999-10-12 2006-07-27 Centre National De La Recherche Scientifique Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
EP1092780A1 (fr) 1999-10-13 2001-04-18 Boehringer Ingelheim International GmbH Virus CELO recombinant et incapable de replication ainsi que l'ADN du virus CELO
ATE428725T1 (de) 2001-04-04 2009-05-15 Pasteur Institut Neurovirulenter stamm des west-nile-virus und anwendungen davon
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
BRPI0211492B1 (pt) 2001-07-27 2016-06-21 Pah W Llc "composição de vacina para uso na prevenção ou melhora de encefalite de west nile em equídeos, e uso de um componente imunogenicamente ativo na preparação da mesma
JP4580650B2 (ja) 2002-01-10 2010-11-17 アメリカ合衆国 西ナイルウイルスにより引き起こされる疾患を予防するために生ウイルスワクチン中に用いるための西ナイルウイルスおよびデングウイルスキメラの構築
SG165155A1 (en) * 2002-02-26 2010-10-28 Maxygen Inc Novel flavivirus antigens
US20030194392A1 (en) * 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
DE10249594A1 (de) * 2002-10-24 2004-05-13 Jassoy, Christian, Dr. Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV)
CA2432738A1 (fr) * 2003-02-26 2004-08-26 Philippe Despres Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104611A1 (en) * 1998-01-16 2003-06-05 Johnston Julie C. Feline immunodeficiency virus gene therapy vectors
FR2777909A1 (fr) * 1998-04-24 1999-10-29 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
WO1999055892A1 (fr) * 1998-04-24 1999-11-04 Institut Pasteur Utilisation de sequences d'adn de structure triplex pour le transfert de sequences nucleotidiques
WO2000075665A1 (fr) * 1999-06-09 2000-12-14 Institut Pasteur Detection precoce des flavivirus en utilisant la clycoproteine ns1
EP1092779A1 (fr) * 1999-10-11 2001-04-18 Institut Pasteur Vecteurs lentiviraux pour la préparation des compositions immunothérapeutiques
CA2456873A1 (fr) * 2003-02-26 2004-08-26 Centre National De La Recherche Scientifique (C.N.R.S.) Proteines du virus du nil occidental, genes codant celles-ci et applications vaccinales, therapeutiques et diagnostiques a base de celles-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARTOSCH B ET AL: "Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 197, no. 5, 3 March 2003 (2003-03-03), pages 633 - 642, XP002267934, ISSN: 0022-1007 *
COLOMBAGE G ET AL: "DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against the Flavivirus, Murray Valley Encephalitis Virus", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 250, no. 1, 10 October 1998 (1998-10-10), pages 151 - 163, XP004445627, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
EP1751291A1 (fr) 2007-02-14
CA2564934C (fr) 2014-07-08
BRPI0510016B1 (pt) 2020-03-10
WO2005111221A1 (fr) 2005-11-24
MXPA06013388A (es) 2007-06-19
FR2870126B1 (fr) 2009-07-17
EP2371966A1 (fr) 2011-10-05
CA2564934A1 (fr) 2005-11-24
US8716013B2 (en) 2014-05-06
CN1981043B (zh) 2010-06-09
BRPI0510016B8 (pt) 2021-05-25
CN1981043A (zh) 2007-06-13
EP2371966B1 (fr) 2015-11-25
US20090214589A1 (en) 2009-08-27
EP1751291B1 (fr) 2013-07-31
BRPI0510016A (pt) 2007-09-18
US20110206710A1 (en) 2011-08-25
JP2008508863A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
FR2870126A1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
BR0014155A (pt) Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino
WO2000077216A3 (fr) Vaccin poxvirus recombine contre le circovirus porcin
HUP0301003A2 (hu) Kazeinből származó peptidek és terápiás alkalmazásuk
HRP20141125T1 (hr) Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
BR0111956A (pt) Tratamento do vìrus do papiloma humano
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
RU2002113920A (ru) Антигенные пептиды neisseria
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
NZ595063A (en) Polypeptides from neisseria meningitidis
JP2003500040A5 (fr)
RU2001134170A (ru) Антигенные пептиды NEISSERIA
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
MA27699A1 (fr) Vaccin contre vhc
BR0016129A (pt) Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto
BR0212625A (pt) peptìdeos derivados de caseìna e usos dos mesmos em terapia
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
MX2024000472A (es) Composicion farmaceutica de virus no encapsulado.
RU2003107837A (ru) Гены и белки и их применения
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
RU2000114245A (ru) Антигены нейссерий

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20